Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Arteriosclerosis Obliterans Market Shows Promising Growth Prospects During the Forecast Period (2026-2036) Amid Evolving Treatment Landscape | DelveInsight

prnewswire.com
LLY Eli Lilly's Orforglipron, an oral GLP-1 receptor agonist, shows potential cardiovascular benefits for arteriosclerosis obliterans and is being investigated for peripheral artery disease (PAD). REGN Regeneron Pharmaceuticals has multiple drugs (REGN7508/Cenvacibart and REGN9933/Amrecibart) under development for arteriosclerosis obliterans, indicating potential future market participation. LSTA Lisata Therapeutics is developing CLBS12, a therapy for arteriosclerosis obliterans, contributing to the pipeline of emerging treatments. ABT Abbott Laboratories is mentioned in the context of Atherosclerosis Market Insights, suggesting potential involvement in related cardiovascular treatments. PFE Pfizer Inc. is listed as a key company in the Atherosclerosis Market, indicating potential relevance to the broader cardiovascular disease landscape. JNJ Johnson and Johnson Services, Inc. is mentioned in relation to Peripheral Artery Disease And Stenosis Treatment Devices, suggesting a role in cardiovascular device markets. MRK Merck & Co., Inc. is listed as a key company in the Peripheral Artery Disease And Stenosis Treatment Devices market, indicating potential involvement in cardiovascular treatments. BMY Bristol Myers Squibb is mentioned as a key company in the Atherosclerosis Market, suggesting potential involvement in cardiovascular disease treatments. AZN AstraZeneca PLC is mentioned in relation to Atherosclerosis Market and Coronary Artery Disease Market, indicating potential involvement in cardiovascular disease treatments. NVS Novartis AG is listed as a key company in the Coronary Artery Disease Market, suggesting potential involvement in cardiovascular disease treatments. AMGN Amgen Inc. is mentioned in the context of Atherosclerosis Market, suggesting potential involvement in cardiovascular disease treatments. GILD Gilead Sciences, Inc. is mentioned in the context of Atherosclerosis Market, suggesting potential involvement in cardiovascular disease treatments. BIIB BioGenCell is listed as a company developing BGC101 for arteriosclerosis obliterans, indicating potential pipeline development.

Arteriosclerosis Obliterans Market Shows Promising Growth Prospects During the Forecast Period (2026-2036) Amid Evolving Treatment Landscape | DelveInsight The arteriosclerosis obliterans market is anticipated to experience steady growth across the 7MM, supported by the increasing prevalence of diabetes and obesity, an aging population, enhanced PAD diagnosis, and growing demand for treatments aimed at reducing amputation risk and improving patients' quality of life. Additionally, the expected launch of emerging therapies such as Orforglipron (LY3502970; Eli Lily), Selexipag (NS-304; Nippon Shinyaku), CLBS12 (Lisata Therapeutics), VT-141 (Venturis Therapeutics), and others will further propel the market growth.

LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Recently published Arteriosclerosis Obliterans Market Insights report includes a comprehensive understanding of current treatment practices, arteriosclerosis obliterans emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Arteriosclerosis Obliterans Market Summary

Discover the future of the arteriosclerosis obliterans market @ https://www.delveinsight.com/report-store/arteriosclerosis-obliterans-market

Key Factors Driving the Growth of the Arteriosclerosis Obliterans Market

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among emerging therapies, selexipag represents one of the most advanced pharmacological candidates specifically targeting arteriosclerosis obliterans-associated intermittent claudication. If successful, selexipag could provide a differentiated oral therapy by improving vascular tone and blood flow beyond currently available symptomatic treatments.

Arteriosclerosis Obliterans Market Analysis

Arteriosclerosis Obliterans Competitive Landscape

Some of the arteriosclerosis obliterans drugs under developent include Orforglipron (LY3502970; Eli Lily), Selexipag (NS-304; Nippon Shinyaku), CLBS12 (Lisata Therapeutics), VT-141 (Venturis Therapeutics), REGN7508/Cenvacibart (Regeneron Pharmaceuticals), REGN9933/Amrecibart (Regeneron Pharmaceuticals), BGC101 (BioGenCell), VS-214 (Vasa Therapeutics), and others.

Eli Lilly's Orforglipron is an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist being developed for metabolic conditions, including obesity and type 2 diabetes, with potential cardiovascular benefits that may be relevant to arteriosclerosis obliterans. The therapy supports glycemic control and weight reduction while addressing cardiometabolic risk factors by enhancing insulin secretion, decreasing glucagon release, and slowing gastric emptying. It is also being investigated as a potential treatment for peripheral artery disease (PAD).

Nippon Shinyaku's Selexipag is an oral, selective prostacyclin (IP) receptor agonist being developed by Nippon Shinyaku for the treatment of arteriosclerosis obliterans accompanied by intermittent claudication. Through activation of the IP receptor, selexipag induces vasodilation, reduces platelet aggregation, and inhibits vascular smooth muscle cell proliferation, which may help improve peripheral blood flow. Selexipag is currently undergoing Phase III clinical development in Japan, where its efficacy is being evaluated based on its potential to improve walking ability and exercise capacity in patients with arteriosclerosis obliterans.

The anticipated launch of these emerging therapies are poised to transform the arteriosclerosis obliterans market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the arteriosclerosis obliterans market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the arteriosclerosis obliterans treatment market @ Arteriosclerosis Obliterans Drugs

Arteriosclerosis Obliterans Epidemiology Segmentation

The arteriosclerosis obliterans epidemiology section provides insights into the historical and current arteriosclerosis obliterans patient pool and forecasted trends for the leading markets. The disease shows a strong age-related pattern, with the highest prevalence observed in the 60–74 years age group, reflecting cumulative exposure to cardiovascular risk factors such as smoking, diabetes, and hypertension.

The arteriosclerosis obliterans treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Arteriosclerosis Obliterans Market Report Metrics

Details

Study Period

2022–2036

Coverage

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Arteriosclerosis Obliterans Epidemiology Segmentation

PAD Diagnosed Prevalent Cases, Arteriosclerosis Obliterans Prevalent Cases, Arteriosclerosis Obliterans Diagnosed Prevalent Cases, Arteriosclerosis Obliterans Cases by Age, Arteriosclerosis Obliterans Cases by Gender, and Arteriosclerosis Obliterans Treated Cases

Key Arteriosclerosis Obliterans Companies

Eli Lily, Nippon Shinyaku, Lisata Therapeutics, Venturis Therapeutics, Regeneron Pharmaceuticals, BioGenCell, Vasa Therapeutics, and others

Key Arteriosclerosis Obliterans Therapies

Orforglipron (LY3502970), Selexipag (NS-304), CLBS12, VT-141, REGN7508/Cenvacibart, REGN9933/Amrecibart, BGC101, VS-214, and others

Scope of the Arteriosclerosis Obliterans Market Report

Download the report to understand the arteriosclerosis obliterans treatment pipeline @ Arteriosclerosis Obliterans Clinical Trials

Table of Contents

1

Arteriosclerosis Obliterans Market Key Insights

2

Arteriosclerosis Obliterans Market Report Introduction

3

Executive Summary

4

Key Events

5

Epidemiology and Market Methodology of Arteriosclerosis Obliterans

6

Arteriosclerosis Obliterans Market Overview at a Glance

6.1

Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])

6.2

Market Share of Arteriosclerosis Obliterans by Therapy (%) in the 7MM in 2025

6.3

Market Share of Arteriosclerosis Obliterans by Therapies (%) in the 7MM in 2036

7

Disease Background And Overview of Arteriosclerosis Obliterans

7.1

Introduction

7.2

Causes

7.3

Signs And Symptoms

7.4

Diagnosis

7.5

Treatment and Management

8

Epidemiology and Patient Population of Arteriosclerosis Obliterans

8.1

Key Findings

8.2

Assumption and Rationale

8.3

Arteriosclerosis Obliterans Prevalent Cases in the 7MM

8.4

The United States

8.4.1

PAD Diagnosed Prevalent Cases in the United States

8.4.2

Arteriosclerosis Obliterans Prevalent Cases in the United States

8.4.3

Arteriosclerosis Obliterans Diagnosed Prevalent Cases in the United States

8.4.4

Arteriosclerosis Obliterans Cases by Age in the United States

8.4.5

Arteriosclerosis Obliterans by Gender in the United States

8.4.6

Arteriosclerosis Obliterans Treated Cases in the United States

8.5

EU4 and the UK

8.6

Japan

9

Patient Journey of Arteriosclerosis Obliterans

10

Emerging Therapies

10.1

Emerging Competitive Landscape of Arteriosclerosis Obliterans

10.2

Orforglipron (LY3502970): Eli Lily

10.2.1

Product Description

10.2.2

Other Developmental Activities

10.2.3

Clinical Development

10.2.3.1

Clinical Trial Information

10.2.4

Safety and Efficacy

10.2.5

Analyst's Views

10.3

Selexipag (NS-304): Nippon Shinyaku

List to be continued……..

11

Arteriosclerosis Obliterans Market: Seven Major Market Analysis

11.1

Key Findings

11.2

Market Outlook of Arteriosclerosis Obliterans

11.3

Conjoint Analysis of Arteriosclerosis Obliterans

11.4

Key Arteriosclerosis Obliterans Market Forecast Assumptions

11.5

Total Market Size of Arteriosclerosis Obliterans in the 7MM

11.6

Market Size of Arteriosclerosis Obliterans by Therapies in the 7MM

11.7

The United States Arteriosclerosis Obliterans Market

11.7.1

Total Market Size of Arteriosclerosis Obliterans in the United States

11.7.2

Market Size of Arteriosclerosis Obliterans by Therapies in the United States

11.8

EU4 and the UK Arteriosclerosis Obliterans Market

11.9

Japan Arteriosclerosis Obliterans Market

12

Unmet Needs of Arteriosclerosis Obliterans

13

SWOT Analysis of Arteriosclerosis Obliterans

14

KOL Views of Arteriosclerosis Obliterans

14.1

Expert/KOL Interview Highlights

15

Market Access and Reimbursement

15.1

The US

15.2

In the EU4 and the UK

15.3

Japan

15.4

Summary and Comparison of Market Access and Pricing Policy Developments in 2025

15.5

Market Access and Reimbursement of Arteriosclerosis Obliterans Therapies

16

Bibliography

17

Arteriosclerosis Obliterans Market Report Methodology

Related Reports

Peripheral Artery Disease Market

Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key peripheral artery disease companies, including Ixaka Ltd (formerly Rexgenero), Hemostemix Inc., Lisata Therapeutics, Caladrius Biosciences, Reven Pharmaceuticals, Inc., Helixmith Co., Ltd, and others.

Atherosclerosis Market

Atherosclerosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atherosclerosis companies, including Bayer, Janssen, Genentech Inc., BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Archer Research, Cardionovum GmbH, Sankyo Pharma GmbH, Daiichi Sankyo Inc., AstraZeneca, Omicron Pharmaceuticals, Abbott, Sanofi, Pfizer, and others.

Coronary Artery Disease Market

Coronary Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Coronary Artery Disease companies, including Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, AskBio, and others.

Peripheral Artery Disease And Stenosis Treatment Devices Market

Peripheral Artery Disease And Stenosis Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key peripheral artery disease and stenosis treatment devices companies, including Medtronic, Koninklijke Philips N.V., B.Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, Rex Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us :

Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com

SOURCE DelveInsight Business Research, LLP